Kolonbo Tai Biological: A400/EP0031 New Drug Market Application Accepted by National Drug Administration.

On the morning of September 23, Coherus BioSciences announced on the Hong Kong Stock Exchange that a new drug application for the reprogrammed small molecule kinase inhibitor project A400 in the company's transfection process has been accepted by the Center for Drug Evaluation of the China National Medical Products Administration. It is used to treat adult patients with RET fusion-positive locally advanced or metastatic non-small cell lung cancer.